Stoke Therapeutics, Inc. (STOK) vs Taysha Gene Therapies, Inc. (TSHA)
Stoke Therapeutics, Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. Stoke Therapeutics, Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.6B and $1.6B). Taysha Gene Therapies, Inc. grew revenue faster over the last twelve months: 19.0% against −86.2%. Taysha Gene Therapies, Inc. has the higher net margin (0.00% vs −753.6%) and the higher return on invested capital (0.00% vs −264.8%). Across the 16 metrics below, Taysha Gene Therapies, Inc. leads on 12 and Stoke Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | STOK | TSHA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (809.69%) | 0.00% | 0.00% |
| Net margin | (753.60%) | 0.00% | 0.00% |
| Free cash flow margin | (654.92%) | 0.00% | 0.00% |
| Return on equity | (61.10%) | (47.05%) | (57.72%) |
| Return on assets | (53.41%) | (37.23%) | (49.22%) |
| Return on invested capital | (264.77%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack